Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Albert David Limited is an India-based pharmaceutical manufacturer specializing in generic drugs, active pharmaceutical ingredients (APIs), and specialty formulations across therapeutic areas including anti-infectives, cardiovascular, and gastrointestinal treatments. The company operates manufacturing facilities in India serving domestic and export markets, with established distribution networks across emerging markets. Recent financial deterioration reflects margin compression and working capital challenges typical of mid-tier generic manufacturers facing pricing pressure and input cost volatility.
Albert David generates revenue through volume-based sales of off-patent generic drugs where pricing power is limited by competition and regulatory price controls in India (NLEM/DPCO). The 66.4% gross margin suggests reasonable manufacturing efficiency, but the collapse to 5.0% net margin indicates elevated SG&A costs, working capital financing expenses, or one-time charges. The company competes on manufacturing cost efficiency, regulatory compliance (WHO-GMP certification), and distribution reach rather than product differentiation. API production provides some vertical integration benefits and export revenue diversification, though commodity-like pricing dynamics limit margin expansion.
API and raw material input costs - particularly Chinese API pricing which affects 66.4% gross margins
Indian rupee exchange rate movements - impacts export realization and imported raw material costs
Domestic pharmaceutical pricing policy changes - NLEM additions or DPCO price revisions directly affect revenue
Working capital management and cash conversion - negative $0.3B operating cash flow indicates collection or inventory issues
New product approvals and ANDA filings - pipeline visibility for revenue diversification
Indian pharmaceutical price control expansion - government may add more drugs to NLEM or impose stricter price caps, compressing margins on key products
API supply chain concentration in China - geopolitical tensions or Chinese environmental regulations could disrupt raw material availability and spike costs
Regulatory compliance costs escalating - FDA/WHO-GMP inspection standards rising, requiring continuous capex investment for quality systems
Intense competition from larger Indian generic manufacturers (Sun Pharma, Dr. Reddy's, Cipla) with superior scale, R&D capabilities, and global distribution networks
Commoditization of generic product portfolio - limited differentiation leads to price-based competition and margin erosion
Export market competition from other low-cost manufacturers in emerging markets reducing pricing power
Negative free cash flow of $0.4B indicates cash consumption requiring external financing or asset sales - sustainability concern if operating performance doesn't improve
Working capital deterioration - negative operating cash flow despite positive net income suggests receivables buildup or inventory obsolescence risk
Low ROE of 2.4% and ROA of 1.8% indicate capital is not generating adequate returns - potential value destruction if margins don't recover
low - Pharmaceutical demand is relatively inelastic as healthcare spending persists through economic cycles. However, generic drug volumes can be affected by government healthcare budget constraints, insurance coverage changes, and consumer ability to afford out-of-pocket medications in emerging markets. The -4.0% revenue decline may reflect market share loss rather than cyclical demand weakness.
Rising interest rates negatively impact Albert David through higher working capital financing costs (evident in the gap between 34.8% operating margin and 5.0% net margin with 0.11 debt/equity suggesting off-balance sheet financing or payables stretching). Higher rates also pressure valuation multiples for low-growth pharmaceutical stocks. However, pharmaceutical companies have limited direct rate sensitivity compared to capital-intensive or consumer discretionary sectors.
Moderate exposure - pharmaceutical distributors and hospital customers in India often operate on extended payment terms (90-180 days), creating working capital strain visible in negative operating cash flow. Tightening credit conditions could worsen collection cycles or require more expensive working capital facilities. The 3.20 current ratio provides liquidity buffer but negative FCF indicates cash consumption.
value - Trading at 1.3x sales and 1.1x book value with 66.4% gross margins suggests deep value opportunity if operational issues are fixable, but -77.2% earnings decline and negative FCF deter growth investors. Current holder base likely includes distressed/special situations investors betting on turnaround or contrarian value investors seeing asset value. High volatility and lack of dividend (given negative FCF) limits appeal to income-focused investors.
high - Small-cap pharmaceutical stock with -17.3% one-year return, operational challenges, and negative cash flow generation creates elevated volatility. Limited analyst coverage and liquidity in Indian small-cap stocks amplifies price swings on news flow. Beta likely above 1.2 relative to Indian equity indices.
